- Poster Presentation
- Open Access
Postoperative serum proteomic profiles and identification of biomarkers with prognosis value in high-risk early breast cancer patients
© BioMed Central 2005
- Published: 17 June 2005
- Postoperative Serum
- Early Breast Cancer Patient
- Metastatic Relapse
- Prognosis Significance
- ProteinChip Array
A significant number of early breast cancer (EBC) patients considered as high risk using standard prognostic factors develop metastasis despite standard adjuvant therapy. A better prediction of clinical outcome is needed to optimize and individualize therapeutic decisions.
To identify a protein signature correlating with metastatic relapse, we performed surface-enhanced laser desorption/ionization-time of flight mass spectrometry profiling of early postoperative serum from 81 high-risk EBC patients. Denatured serum samples were fractionated and the resulting fractions were incubated with ProteinChip arrays (Ciphergen Biosystems, Fremont, CA, USA).
Several protein peaks were differentially expressed according to clinical outcome (long-term metastasis-free survival versus metastatic relapse). By combining partial least squares and logistic regression methods, we built a multiprotein model that correctly predicted outcome in 83% of patients. Consistency and robustness of the model were verified using leave-one-out cross-validation. Five-year metastasis-free survival in 'good prognosis' and 'poor prognosis' patients as defined using the multiprotein index were strikingly different (83% vs 22%, P < 0.0001, log-rank test). In a multivariate Cox regression including conventional pathological factors and multiprotein index, only the latter retained independent prognosis significance for metastatic relapse. Major components of the multiprotein index were identified and included haptoglobin, C3a complement fraction, transferrin, apolipoprotein C1 and apolipoprotein A1.
Postoperative serum protein pattern may have an important prognostic value in high-risk EBC. In addition, it may reveal new insights on the metastatic process while providing new targets for future therapeutics.